Citations

Clear

3057 citation(s) found for "Cd, Johnson".

The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results From a Randomized Controlled Trial
Avenido, Francis Ryan R., Mitchell, N. Reed, Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta, McDonough, Daniel J. , Rydell, Sarah A. , Pereira, Mark, Pereira, Mark A. , Sharma, Shweta , McDonough, Daniel J , Pereira, Mark A , Demmer, Ryan T. , Pope, Zachary , Avenido, Francis Ryan, Johnson, Stephen, Johnson, Abigail J.

Mayo Clinic

Diabetes Obesity and Cardiometabolic CARE | March 16, 2026 | Volume: 1 | Issue: 2 | Pages: 219-229

10.2337/doc25-0067 | PMID 42577916 Get It

OBJECTIVE To test the effect of physical activity on the gut microbiome and circulating short-chain fatty acids (SCFAs) among sedentary adults with prediabetes and overweight or obesity. RESEARCH DESIGN AND METHODS In a pilot and feasibility trial, we randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) intervention: invited to engage in home-based moderate-intensity walking 3×/week for 30 min/session in weeks 1–4 and for 45 min/session during weeks 5–8 of the 8-week intervention; or 2) control: maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with SCFAs measured from serum collected at baseline and week 8. Taxonomic and functional profiling was performed on the metagenomic reads; α-diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for α-diversity and SCFA levels. RESULTS We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase, and 77 were randomized. Participants were mean (SD) 51.4 (8.9) years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3 (13.2) mg/dL, while mean BMI was 34.4 (5.7) kg/m2. Compared with the control group, the intervention group experienced decreased α-diversity as characterized by Shannon, Richness, and Faith diversity indices by intervention week 8 (P < 0.05). Changes in SCFA levels were not statistically significant different in intervention versus control. CONCLUSIONS Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight or obesity and prediabetes.
Temporal single-cell analysis reveals age-associated delay in immune resolution after respiratory viral infection
Wu, Yue , Li, Chaofan , Tang, Jinyi, Cheon, In Su , Zhu, Bibo, Zhang, Ruixuan, Hu, Shengen Shawn, Johnson, Aaron J, Zong, Hui, dong, Haidong, Gao, Xiaochen , Fain, Cori E. , Narasimhan, Harish , Santos, Gislane de Almeida , Ayasoufi, Katayoun , Johnson, Aaron J. , Zong, Hui , Zang, Chongzhi , Dong, Haidong , Sun, Jie

Mayo Clinic

No container title available | March 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.109988.1 Get It

Aging is a major risk factor for increased morbidity and mortality following acute respiratory virus infections. To elucidate the immune determinants underlying viral pathogenesis and delayed lung repair in the aged lung, a comprehensive time-course study was conducted. Single-cell RNA sequencing (scRNAseq) and high-dimensional flow cytometry were utilized to compare lungs from young and aged mice infected with influenza A virus (IAV). Aged hosts displayed diminished alveolar macrophage (AM) and dendritic cell (DC) but elevated monocyte-derived macrophage (MoM) and interstitial macrophage (IM) presence following infection. Additionally, enhanced accumulation of adaptive immune cells, including CD4+ tissue-resident helper (TRH) cells, CD8+ tissue-resident memory (TRM) cells, and a B cell subset resembling age-associated B cells, was observed in the memory phase. Pathway analysis revealed that elevated type I and II interferon (IFNα/γ) signaling, especially in MoM/IM subsets, distinguished the aged hosts from the young. Inhibition of IFNα/γ signaling after viral clearance improved long-term respiratory outcomes and reduced both IM and TRH populations in aged mice. These findings highlight the pivotal role of IFNα/γ signaling, likely within MoM/IM subsets, in driving the exuberant persistence of adaptive immune cells and chronic immunopathology in the aged lung following acute viral infection.
Temporal single-cell analysis reveals age-associated delay in immune resolution after respiratory viral infection
Wu, Yue , Li, Chaofan , Tang, Jinyi, Cheon, In Su , Zhu, Bibo, Zhang, Ruixuan, Hu, Shengen Shawn, Johnson, Aaron J, Zong, Hui, dong, Haidong, Gao, Xiaochen , Fain, Cori E. , Narasimhan, Harish , Santos, Gislane de Almeida , Ayasoufi, Katayoun , Johnson, Aaron J. , Zong, Hui , Zang, Chongzhi , Dong, Haidong , Sun, Jie

Mayo Clinic

No container title available | March 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.109988 Get It

Aging is a major risk factor for increased morbidity and mortality following acute respiratory virus infections. To elucidate the immune determinants underlying viral pathogenesis and delayed lung repair in the aged lung, a comprehensive time-course study was conducted. Single-cell RNA sequencing (scRNAseq) and high-dimensional flow cytometry were utilized to compare lungs from young and aged mice infected with influenza A virus (IAV). Aged hosts displayed diminished alveolar macrophage (AM) and dendritic cell (DC) but elevated monocyte-derived macrophage (MoM) and interstitial macrophage (IM) presence following infection. Additionally, enhanced accumulation of adaptive immune cells, including CD4+ tissue-resident helper (TRH) cells, CD8+ tissue-resident memory (TRM) cells, and a B cell subset resembling age-associated B cells, was observed in the memory phase. Pathway analysis revealed that elevated type I and II interferon (IFNα/γ) signaling, especially in MoM/IM subsets, distinguished the aged hosts from the young. Inhibition of IFNα/γ signaling after viral clearance improved long-term respiratory outcomes and reduced both IM and TRH populations in aged mice. These findings highlight the pivotal role of IFNα/γ signaling, likely within MoM/IM subsets, in driving the exuberant persistence of adaptive immune cells and chronic immunopathology in the aged lung following acute viral infection.
Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
Schindler, Suzanne E., Arias, Jalayne J., Beasley, Brent W. , Farrar, Gill , Fowler, Nicole R., Jack, Clifford R., Jönsson, Linus, Joyce, Geoffrey , Lansdall, Claire J., Maruff, Paul, Mattsson‐Carlgren, Niklas, Mummery, Catherine J. , Murphy, Jennifer, Okhravi, Hamid , Petersen, Ronald C., Raman, Rema, Randolph, Christopher , Sass, Marie Reeberg , Reiman, Eric M., Salvadó, Gemma, Schöll, Michael, Siemers, Eric , Sperling, Reisa A., Thornton‐Wells, Tricia, Tortelli, Rosanna , Tosun, Duygu, Vandevrede, Lawren, Weninger, Stacie, Wessels, Alette M. , Zhou, Jin, Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Jönsson, Linus , Schindler, Suzanne E. , Hansson, Oskar , Algeciras‐Schimnich, Alicia , Arias, Jalayne J. , Fowler, Nicole R. , Hartz, Sarah M. , Jack, Clifford R. , Maruff, Paul , Mattsson, Niklas , Murphy, Jennifer, Petersen, Ronald C. , Raman, Rema , Reiman, Eric M. , Salvadó, Gemma , Sperling, Reisa Anne , Thornton‐Wells, Tricia A., VandeVrede, Lawren , Villain, Nicolas , Zhou, Jin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | March 12, 2026 | Volume: 12 | Issue: 1 | Pages: No page available

10.1002/trc2.70216 Get It

Abstract Advances in biomarker technology, digital cognitive assessments, and amyloid‐targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD). These advances also create new possibilities for intervention before the onset of cognitive impairment. This paradigm shift has increased the focus on Stages 1 and 2 of AD, in which individuals are cognitively unimpaired but exhibit biological evidence of disease. While early identification of AD offers an opportunity to intervene early to delay progression and preserve quality of life, it also presents complex challenges related to communicating diagnostic results to patients and their families, contextualizing the cost effectiveness of early diagnosis and treatment, and implementation of and equitable access to treatments. Recent, successfully enrolled, preclinical AD trials highlight the complex strategies required to identify asymptomatic, biomarker‐positive individuals on a large scale, and demonstrate critical knowledge gaps in inclusion, follow‐up, and long‐term outcome measurement. The Spring 2025 Alzheimer's Association Research Roundtable (AARR) meeting brought together academics, clinicians, industry, and regulatory leaders to exchange perspectives on current challenges, key learnings, and potential strategies for identifying and treating individuals in very early stages of AD, effectively and safely. This paper presents key takeaways from the Spring 2025 AARR meeting. Highlights New criteria for Alzheimer's disease (AD) enable early identification of AD pathology. Blood tests and digital cognitive assessment tools may facilitate early and personalized care. Plasma biomarkers may be scalable in clinical settings but need confirmation or follow‐up assessments in those individuals with equivocal results. Early therapy shows best results in people with lower initial amyloid and tau burden.
Development of A Screening Tool to Predict Post Intensive Care Syndrome (PICS) in Critically Ill Adults in a Prospective Cohort
Valle, Kathryn T. del , Harris, B. , Clark, Matthew M. , Philbrick, Kemuel L. , Cipriani, Ellie, Cornelius, P., SCHULTE, PHILLIP, Sonsalla, K., Guntupalli, Siva Kamal, Johnson, Andrea, Muir, Kristin, Karnatovskaia, Lioudmila V. , Del Valle, Kathryn T , Harris, Benjamin R E , Cornelius, Patrick , Sonsalla, Kelly, Karnatovskaia, Lioudmila , LeMahieu, Allison , Schulte, Phillip J.

Mayo Clinic

Journal of Intensive Care Medicine | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261425642 | PMID 41793150 Get It

Purpose Survivors of critical illness often acquire significant physical, cognitive, and psychological burdens following their intensive care unit (ICU) stay, termed “post-intensive care syndrome” (PICS). Screening for PICS is generally not performed outside of research settings largely due to lack of a simple assessment tool and time constraints. Methods This was a prospective cohort study at a single academic medical center in the USA. We included adults (18 years or older) who spent greater than 48 h in any ICU within the medical center. Following transfer out of the ICU and at 3 months, psychological, cognitive, and physical functioning were assessed using the Hospital Anxiety and Depression Scale, Impact of Event Scale-Revised, Montreal Cognitive Assessment-blind, and Barthel Index. We compared these validated questionnaires to a brief, 15-item PICS screening tool (5 questions/domain) that was developed by our multidisciplinary study team and administered to study participants after ICU discharge to general care. The primary objectives of this study were to assess the ability of validated screening tools administered at ICU discharge to predict PICS at 3 months and develop a novel screening tool for identifying patients at risk of PICS. Major Findings 191 participants completed the initial questionnaire, and 109 (56%) completed the 3-month follow-up. PICS tool scores were compared to 3-month follow-up data from validated questionnaires to evaluate predictive performance. Overall, the screening tool weakly-to-moderately correlated with continuous outcomes of the validated measures at 3-month follow-up. When evaluating sensitivity and specificity for individual domains, the screening tool had an area under curve of >0.7 for all three domains, indicating moderate-to-good sensitivity and specificity. Conclusions We developed a brief PICS screening tool that is feasible to use without prior training that modestly predicted the development of PICS following ICU stay.
Design and Implementation of a State‐Wide Network for Near Real‐Time Public Health Surveillance and Research: The Minnesota Electronic Health Record Consortium Experience
Johnson, Steven G. , Chamberlain, Alanna M., Drawz, Paul E. , Dudley, R. Adams, Waring, Stephen C. , Winkelman, Tyler, Bodurtha, Peter , Bergmann, Kelly R. , Essien, Inih , Rai, Nayanjot K., Patnoe, Samuel T. , Waring, Stephen C. , Johnson, Steve , Winkelman, Tyler N A , Bergmann, Kelly , Drawz, Paul , Chamberlain, Alanna M. , Dudley, R. Adams , Kaur, Nayanjot , Margolis, Karen L.

Mayo Clinic

Learning Health Systems | March 8, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/lrh2.70070 | PMID 41743490 Get It

ABSTRACT Objective The Minnesota Electronic Health Record Consortium (MNEHRC) was established during the early days of the COVID‐19 pandemic to provide data for public health surveillance from the eleven largest health care systems in Minnesota. Methods This is a descriptive study of the Consortium, which is a federated network that implements best practices for governance and data infrastructure to support public health surveillance and clinical research. We conducted an analysis of the Consortium members, governance structure, infrastructure, and the characteristics of the patient population. Results The Consortium health systems collect information from 105 hospitals, 773 clinics, 100 emergency departments and 29 040 providers. Information about the health systems and the demographic and clinical characteristics of its 5 471 367 patients is provided, which represents more than 90% of the patients in Minnesota. This manuscript also details the MNEHRC governance structure, working groups, data use agreements and technical infrastructure. The Consortium has produced several studies with state‐wide impact. One study, Health Trends Across Communities in Minnesota, is described in detail to illustrate aspects of this collaboration. Conclusion MNEHRC has been a successful collaboration and vital resource for public health surveillance in the state of Minnesota. Initially, the Consortium focused on surveillance related to COVID‐19 infections and vaccinations but has recently expanded into other public health and chronic disease research.
Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps
Brailovsky, Yevgeniy, Hanna, Mazen, Witteles, Ronald, Vaishnav, Joban , Griffin, Jan Marie, Garcia-Pavia, Pablo, Wolinsky, David G. , Karam, Chafic, Lachmann, Helen J, Gertz, Morie A., Bampatsias, Dimitrios, Hsu, Kristen , Johnson, Phaedra Theodora, Zigterman, Jamie, Kazemzadeh, Ana Carolina, Maurer, Mathew S., Wechalekar, Ashutosh D., Karam, Chafic , Chakraborty, Rajshekhar , Brailovsky, Yevgeniy , Garcia-Pavia, Pablo , Wolinsky, David , Karam, Chafic , Lachmann, Helen , Hsu, Kristen , Johnson, Phaedra , Zigterman, Jamie , Chakraborty, Rajshekhar , Brailovsky, Yevgeniy , Hanna, Mazen , Witteles, Ronald , Hoffman, James Edward, Griffin, Jan M. , Lachmann, Helen J. , Gertz, Morie A. , Boursiquot, Brian C. , Bampatsias, Dimitrios, Maurer, Mathew S , Wechalekar, Ashutosh D.

Mayo Clinic

Blood | March 4, 2026 | Volume: 147 | Issue: 21 | Pages: 2448-2462

10.1182/blood.2025031651 | PMID 41779722 Get It

Abstract The therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-year overall survival in the landmark ANDROMEDA trial. However, the current prognostic models were developed using patient populations treated with now-suboptimal therapies, creating a critical gap between risk stratification models and contemporary outcomes. This comprehensive review analyzes prognostic factors and progression biomarkers in AL, categorizing them into disease-specific (clone-related and organ-related) and patient-specific factors. Notably, traditional baseline biomarkers including difference between involved and uninvolved free light chains and bone marrow plasma cell burden are losing prognostic significance with effective clone-directed therapies. Emerging approaches show promise, including dynamic markers such as minimal residual disease by free light chain mass spectrometry, cardiac imaging parameters such as global longitudinal strain, and functional measures. There is an urgent need for validation studies and prognostic model refinement to identify patients at high risk who may benefit from interventions beyond anti–plasma cell therapy.
PSA Zero Radiographic Disease Progression on PSMA PET/CT
Mahmoud, Ahmed M., Day, Carter, Ahmed, E Al-Marzouk, Ahmed, M, Haloi, Rimki , Mahon, Mindie, Nikanpour, Yalda , Orme, Jacob J. , Kendi, MD Ayse Tuba, Johnson, G B, Kwon, E., Andrews, Jack R. , Ahmed, Mohamed E. , Kendi, A. Tuba , Mahmoud, Ahmed , Mahmoud, Ahmed M , Ahmed, Eman E , Ahmed, Mohamed , Childs, Daniel S , Orme, Jacob J , Kendi, A Tuba , Mahon, Mindie, Childs, Daniel S. , Johnson, Geoffrey B , Kwon, Eugene D.

Mayo Clinic

Cancers | March 4, 2026 | Volume: 18 | Issue: 5 | Pages: 831

10.3390/cancers18050831 | PMID 41827764 Get It

Background and Objective: Radiographic progression in prostate cancer (PCa) can occur even when prostate-specific antigen (PSA) levels are undetectable. We aimed to determine the frequency and characteristics of radiographic disease progression (rDP) on PSMA PET/CT in patients with undetectable PSA, referred to as PSA zero rDP. Methods: We analyzed the Mayo Clinic PSMA PET Prostate Cancer Registry to identify patients with rDP on PSMA PET/CT despite undetectable PSA levels. Disease progression was confirmed via biopsy or treatment response. The cohort included patients with non-metastatic and metastatic hormone-sensitive disease, as well as those with castration-resistant prostate cancer at the time of imaging. Overall survival (OS) was estimated using the Kaplan–Meier method. Group comparisons were performed with the log-rank test. Univariate Cox regression was used to identify factors associated with poor OS. Key findings and Limitations: Among 2141 patients imaged between 2021 and 2023, 257 (12%) had PSA zero rDP. Sixty-one percent had initially localized disease; 39% had de novo metastatic disease. Median (IQR) time from diagnosis to PSA zero rDP was 51.9 (18.4–115.5) months. A total of 184 patients (72%) progressed to castration-resistant PCa. Sites of rDP included bone (57%), visceral (15%), lymph node (18%), and local recurrence (10%). During median follow-up of 8.1 (3.5–11.9) months, 5% of patients died. Only visceral metastases were significantly associated with poorer OS (p < 0.0001). Conclusions and Clinical Implications: Prostate cancer patients frequently develop metastatic disease with undetectable PSA values. Our findings suggest the use of periodic advanced imaging techniques, irrespective of PSA value, for more prompt detection and early management of disease progress.
Positron Emission Tomography/Computed Tomography in Cardiac Implantable Electronic Device Infections: Insights From the Emerging Infections Network
McHugh, Jack , Cuervo, Guillermo, Abu-Zeinah, Khalid , Beekmann, Susan E. , Polgreen, Philip M. , Deshmukh, Abhishek J, Johnson, G B, Saleh, Omar M Abu, Baddour, L M, Baddour, Larry M. , Johnson, Geoffrey B. , Cuervo, Guillermo , Chesdachai, Supavit , McHugh, Jack , Cuervo, Guillermo , Abu-Zeinah, Khalid , Beekmann, Susan E , Polgreen, Philip M , Deshmukh, Abhishek J , Johnson, Geoffrey B , Abu Saleh, Omar , DeSimone, Daniel C , Baddour, Larry , Chesdachai, Supavit , Deshmukh, Abhishek , Saleh, Omar Abu , DeSimone, Daniel C.

Mayo Clinic

Open Forum Infectious Diseases | March 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/ofid/ofag109 | PMID 41852557 Get It

Abstract The practice patterns of fluorine 18–labeled fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG PET/CT) use in cardiac implantable electronic device infection remain undefined. Among 258 Emerging Infections Network respondents, 69% reported never or rarely using [18F] FDG PET/CT. Limited access and insurance barriers were the most common obstacles.
Is There a Microbiological Basis for Increased Breast Cancer Risk in Women with High Mammographic Density?
Sample, Jack W., Redaelli, Matteo , Johnson, SH, Walther-Antonio, Marina, Hieken, Tina J. , Johnson, Stephen , Sample, Jack W. , Hieken, Tina J , Sample, Jack W , Johnson, Stephen , Chen, Jun , Hoskin, Tanya L.

Mayo Clinic

Applied Microbiology | March 3, 2026 | Volume: 6 | Issue: 3 | Pages: 39

10.3390/applmicrobiol6030039 Get It

(1) Background: Mammographic breast density (MBD) is a well-established predictor of breast cancer risk, yet the biological mechanisms underlying this association remain incompletely understood. MBD is characterized by alterations in breast stromal architecture, including increased collagen deposition and changes in immune cell composition. Given emerging evidence that the breast harbors a resident microbiome, we investigated whether the breast tissue microbiome correlates with MBD. (2) Methods: Adjacent normal breast tissue was collected under sterile conditions from 33 women undergoing surgery for benign or malignant breast disease. DNA was extracted and subjected to 16S rRNA gene sequencing (Illumina MiSeq). (3) Results: We observed a non-significant trend toward lower α-diversity in high-MBD samples compared to low-MBD samples, p = 0.13. β-Diversity analyses identified a modest association between MBD and microbial community composition (MiRKAT p = 0.049). A random forest-based model incorporating genus-level relative abundances improved prediction of MBD over clinical characteristics alone, identifying Corynebacterium (Actinobacteria) and other genera as key predictors. (4) Conclusions: Breast tissue microbial features vary with mammographic breast density, suggesting a potential association with density-associated breast cancer risk. These exploratory findings warrant validation in larger cohorts to better elucidate biological mechanisms and clinical relevance.